Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (date of earliest event reported): May 5, 2011

 

 

MEDNAX, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

Florida   001-12111   26-3667538

(State or Other Jurisdiction of

Incorporation)

 

(Commission File

Number)

  (IRS Employer Identification No.)

1301 Concord Terrace

Sunrise, Florida 33323

(Address of principal executive office) (zip code)

Registrant’s telephone number, including area code (954) 384-0175

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 


Item 5.07 Submission of Matters to a Vote of Security Holders.

MEDNAX, Inc., a Florida corporation (the “Company”), held its 2011 Annual Shareholders’ Meeting (the “Annual Meeting”) on May 5, 2011. Of the 48,024,694 shares outstanding and entitled to vote, 43,238,954 shares were represented, constituting a quorum. The final results for each of the matters submitted to a vote of shareholders at the Annual Meeting are as follows:

Proposal 1: All of the Board’s nominees for Director were elected to serve until the Company’s 2012 Annual Meeting or until their respective successors are elected and qualified, by the votes set forth in the table below:

 

Name

   For      Withheld      Broker
Non-Vote
 

Cesar L. Alvarez

     33,830,646         7,302,558         2,105,750   

Waldemar A. Carlo, M.D.

     38,422,127         2,711,077         2,105,750   

Michael B. Fernandez

     38,424,857         2,708,347         2,105,750   

Roger K. Freeman, M.D.

     35,688,262         5,444,942         2,105,750   

Paul G. Gabos

     40,578,334         554,870         2,105,750   

Dany Garcia

     40,578,134         555,070         2,105,750   

Pascal J. Goldschmidt, M.D.

     39,733,345         1,399,859         2,105,750   

Manuel Kadre

     39,476,896         1,656,308         2,105,750   

Roger J. Medel, M.D.

     38,842,961         2,290,243         2,105,750   

Donna E. Shalala, Ph.D.

     38,372,481         2,760,723         2,105,750   

Enrique J. Sosa, Ph.D.

     40,576,419         556,785         2,105,750   

 

 

Proposal 2: The appointment of PricewaterhouseCoopers LLP as the Company’s independent registered certified public accounting firm for the 2011 fiscal year was ratified by the shareholders, by the votes set forth in the table below:

 

For

   Against      Abstained      Broker
Non-Vote
 

42,000,670

     1,234,139         4,145         0   


Proposal 3: The shareholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, by the votes set forth in the table below:

 

For

   Against      Abstained      Broker
Non-Vote
 

36,857,819

     3,061,203         1,214,182         2,105,750   

 

Proposal 4: The shareholders indicated, on a non-binding, advisory basis, a preference to hold future advisory votes on executive compensation every year, by the votes set forth in the table below:

 

Every Year

   Every
Two
Years
     Every Three
Years
     Abstained      Broker
Non-Vote
 

29,821,161

     44,198         10,044,565         1,223,280         2,105,750   


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    MEDNAX, INC.
Date: May 5, 2011     By:   /s/ Vivian Lopez-Blanco
        Chief Financial Officer